Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Skin Neoplasms 1Keratosis, Actinic 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Diclofenac × Dermatologic × Clear all
NCT01962987 2020-07-20

A Study Comparing Diclofenac Sodium Gel 3% to SolarazeĀ® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Actavis Inc.

Phase 3 Completed
476 enrolled 10 charts
Dermatologic

Keratosis, Actinic

NCT00601640 2017-03-23

Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

University of Arizona

Phase 2 Completed
184 enrolled 9 charts
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔